


































Pharmaceuticals —

Pipeline Overview and Progress

April 30, 2024 –
Investor Relations



Pharmaceuticals – Pipeline Overview¹ (as of April 30, 2024)

Phase I	Phase II	Phase III
HER2/mEGFR Inhibitor (BAY 2927088)  ●	Congestive Heart Failure rAAV Gene Therapy (AB-1002)  ● # Congestive Heart Failure (GenePHIT)	Darolutamide (AR Inhibitor)  ○ # Prostate Cancer (mHSPC) (ARANOTE) # Adjuvant Prostate Cancer (DASL-HiCaP) # Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)
DGKzeta Inhibitor (BAY 2965501)  ●	Anti-a2AP (BAY 3018250)  ● # Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)	Finerenone (MR Antagonist)  ○ # Heart Failure (HFmr/pEF) (FINEARTS-HF) # Non-diabetic Chronic Kidney Disease (FIND-CKD) # Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)
CCR8 Ab (BAY 3375968)  ●	Runcaciguat (sGC Activator) (BAY 1101042)  ● # Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)	Vericiguat (sGC Stimulator)  ○ # Heart Failure (HFrEF) (VICTOR ²)
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)  ●		Asundexian (FXIa Inhibitor)  ● # 2 ^o Stroke Prevention (OCEANIC-STROKE)
DGKalpha Inh (BAY 2862789)  ●		Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ● # Vasomotor Symptoms (OASIS)
225Ac-Pelgifatamab (BAY 3546828)  ●		Aflibercept 8mg (VEGF Inhibitor)  ○ # Retinal Vein Occlusion (QUASAR)
VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)  ●		Gadoquatrane (High Relaxivity Contrast Agent)  ● # Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OBR)
225Ac-PSMA-Trillium (BAY 3563254)  ●		
sGC Activator Oral (BAY 3283142)  ●		
SEMA 3a (BAY 3401016)  ●		
Anti-coagulant (BAY 3389934)  ●		
Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●		
Parkinson's Disease rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-PD)  ●		
Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)  ●		
Pompe Disease rAAV Gene Therapy (ACTUS-101)  ●		
Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101)  ●		
LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)  ●		
GPR84 Antagonist (BAY 3178275)  ●		
BAY 2701250  ●		
		Submissions
		Aflibercept 8mg (VEGF-Inhibitor)  ○ # CN: Neovasc. Age-rel. Macular Degen. (nAMD)
		Acoramidis⁴ (TTR-Stabilizer)  ● # EU: Transthyretin Amyloid Cardiomyopathy

- Oncology
- Cardiovascular+³
- Neurology & Rare Diseases
- Immunology
- Others

- New molecular entity
- Life cycle management



¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Conducted by Merck & Co ³ Including Precision Cardiovascular, Nephrology & Acute Care
⁴ Exclusive commercialization rights acquired for EU markets; pending marketing authorization approval. Submission to EMA under responsibility of BridgeBio



Pharmaceuticals – Pipeline Details Phase III¹ (as of April 30, 2024)

Therapeutic Area	Candidate Medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Oncology	Darolutamide (AR Inhibitor)		Orion	Prostate Cancer (mHSPC) (<i>ARANOTE</i>)	NCT04736199	Q2 2024	Study ongoing
				Adjuvant Prostate Cancer (<i>DASL-HiCaP</i>)	NCT04136353	Q1 2028	Study ongoing
				Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (<i>ARASTEP</i>)	NCT05794906	Q1 2027	Study ongoing
Cardiovascular+ ³	Finerenone (MR Antagonist)		Bayer	Heart Failure (HFmr/pEF) (<i>FINEARTS-HF</i>)	NCT04435626	Q2 2024	Study ongoing
				Non-diabetic Chronic Kidney Disease (<i>FIND-CKD</i>)	NCT05047263	Q1 2026	Study ongoing
				Chronic Kidney Disease in Type 1 Diabetes (<i>FINE-ONE</i>)	NCT05901831	Q3 2025	Study ongoing
	Vericiguat (sGC Stimulator)		Bayer	Heart Failure (HFrEF) (<i>VICTOR</i> ²)	NCT05093933	Q1 2025	Study ongoing
	Asundexian (FXIa Inhibitor)		Bayer	2° Stroke Prevention (<i>OCEANIC-STROKE</i>)	NCT05686070	Q4 2025	Study ongoing
Others	Elinzanetant (Neurokinin-1,3 Rec Antagonist)		KaNDy	Vasomotor Symptoms (<i>OASIS-1, OASIS-2, OASIS-3, OASIS-4, NIRVANA</i> ⁴)	NCT05042362	Q3 2023	Study completed
					NCT05099159	Q2 2023	
					NCT05030584	Q1 2023	
	Aflibercept 8mg (VEGF Inhibitor)		Regeneron	Retinal Vein Occlusion (RVO) (<i>QUASAR</i>)	NCT05850520	Q4 2024	Study ongoing
	Gadoquatrane (High Relaxivity Contrast Agent)		Bayer	Magnetic Resonance Imaging (<i>QUANTI-CNS, QUANTI-OBR</i>)	NCT05915702 NCT05915728	Q4 2024 Q4 2024	Studies ongoing




¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Conducted by Merck & Co

³ Including Precision Cardiovascular, Nephrology & Acute Care

⁴ Phase II pilot study on sleep disturbances associated with menopause



Pharmaceuticals – Pipeline Details Phase II¹ (as of April 30, 2024)

Therapeutic Area	Candidate Medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Cardiovascular+ ²	Congestive Heart Failure rAAV Gene Therapy (AB-1002)		AskBio	Congestive Heart Failure (<i>GenePHIT</i>)	NCT05598333	Q4 2029	Study ongoing
	Anti-a2AP (BAY 3018250)		Bayer	Acute Ischemic Stroke; Pulmonary Embolism (<i>SIRIUS</i>)	NCT06149520	Q2 2025	Study ongoing
Others	Runcaciguat (sGC Activator) (BAY 1101042)		Bayer	Non-prolif. Diabetic Retinopathy (NPDR) (<i>NEON-NPDR</i>)	NCT04722991	Q2 2024	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Including Precision Cardiovascular, Nephrology & Acute Care





Pharmaceuticals – Pipeline Details Phase I¹ (as of April 30, 2024)

Therapeutic Area	Candidate Medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Oncology	HER2/mEGFR Inhibitor (BAY 2927088)		Bayer/Broad Institute	Adv. Non-small Cell Lung Cancer w EGFR Mut. and/or HER2 Mut.	NCT05099172	Q4 2027	Study ongoing
	DGKzeta Inhibitor (BAY 2965501)		Bayer/DKFZ	Advanced Solid Tumors	NCT05614102	Q3 2026	Study ongoing
	CCR8 Ab (BAY 3375968)		Bayer	Advanced Solid Tumors	NCT05537740	Q4 2026	Study ongoing
	VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)		Vividion	Advanced Solid Tumors	NCT05954312	Q4 2027	Study ongoing
	DGKalpha Inhibitor (BAY 2862789)		Bayer/DKFZ	Advanced Solid Tumors	NCT05858164	Q3 2025	Study ongoing
	225Ac-Pelgifatamab (BAY 3546828)		Lantheus	Advanced Prostate Cancer	NCT06052306	Q2 2027	Study ongoing
	VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)		Vividion	Advanced Solid and Hematologic Tumors	NCT06188208	Q4 2027	Study ongoing
	225Ac-PSMA-Trillium (BAY 3563254)		Noria/PSMA Therapeutics*	Advanced Prostate Cancer	NCT06217822	Q2 2027	Study ongoing
Cardiovascular+ ²	sGC Activator (BAY 3283142)		Bayer	Chronic Kidney Disease (CKD)	NCT05491642	Q1 2023	Study completed
	SEMA 3a (BAY 3401016)		Bayer/Evotec	Alport Syndrome	n/a	Q3 2024	Study ongoing
	Anti-coagulant (BAY 3389934)		Bayer	Anti-coagulation	n/a	Q2 2024	Study ongoing
Neurology / Rare Diseases	Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)		BlueRock	Parkinson's Disease	NCT04802733	Q2 2023	Study ongoing
	Parkinson's Disease rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-PD)		AskBio	Parkinson's Disease	NCT04167540	Q4 2023	Study ongoing
	Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)		AskBio	Multiple System Atrophy	NCT04680065	Q4 2025	Study ongoing
	Pompe Disease rAAV Gene Therapy (ACTUS-101)		AskBio	Pompe Disease	NCT03533673	Q3 2022	Study ongoing
	Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101)		AskBio	Huntington's Disease	NCT05541627	Q4 2025	Study ongoing
	LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)		AskBio	Limb Girdle Muscular Dystrophy	NCT05230459	Q4 2028	Study ongoing
Others	GPR84 Antagonist (BAY 3178275)		Bayer	Diabetic Neuropathic Pain	n/a	Q1/2024	Study ongoing
	BAY 2701250		Bayer	Pulmonary Hypertension	NCT06048120	Q1 2025	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Including Precision Cardiovascular, Nephrology & Acute Care

*Bayer acquired Noria and PSMA Therapeutics in 2021



Pharmaceuticals – Pipeline Details Oncology¹ (as of April 30, 2024)

Candidate medication	Indication	Modality	Compound Origin	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Darolutamide (AR Inhibitor)	Prostate Cancer (mHSPC) (ARANOTE)		Orion				NCT04736199	Q2 2024	Study ongoing
	Adjuvant Prostate Cancer (DASL-HiCaP)						NCT04136353	Q1 2028	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)						NCT05794906	Q1 2027	Study ongoing
HER2/mEGFR Inhibitor (BAY 2927088)	Advanced Non-small Cell Lung Cancer with EGFR Mutation and/or HER2 Mutation		Bayer/Broad Institute				NCT05099172	Q4 2027	Study ongoing
DGKzeta Inhibitor (BAY 2965501)	Advanced Solid Tumors		Bayer/DKFZ				NCT05614102	Q3 2026	Study ongoing
CCR8 Ab (BAY 3375968)	Advanced Solid Tumors		Bayer				NCT05537740	Q4 2026	Study ongoing
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)	Advanced Solid Tumors		Vividion				NCT05954312	Q4 2027	Study ongoing
DGKalpha Inh (BAY 2862789)	Advanced Solid Tumors		Bayer/DKFZ				NCT05858164	Q3 2025	Study ongoing
225Ac-Pelgifatamab (BAY 3546828)	Advanced Prostate Cancer		Lantheus				NCT06052306	Q2 2027	Study ongoing
VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)	Advanced Solid and Hematologic Tumors		Vividion				NCT06188208	Q4 2027	Study ongoing
225Ac-PSMA-Trillium (BAY 3563254)	Advanced Prostate Cancer		Noria/PSMA Therapeutics*				NCT06217822	Q2 2027	Study ongoing

Protein Therapeutics
 Cell Therapy
 Contrast Agent
 Genetic Medicine
 Radionuclide Therapy
 Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

*Bayer acquired Noria and PSMA Therapeutics in 2021



Pharmaceuticals – Pipeline Details Cardiovascular+^{1,3} (as of April 30, 2024)

Candidate Medication	Indication	Modality	Compound Origin	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Finerenone (MR Antagonist)	Heart Failure (HFmr/pEF) (<i>FINEARTS-HF</i>)		Bayer				NCT04435626	Q2 2024	Study ongoing
	Non-diabetic CKD (<i>FIND-CKD</i>)			NCT05047263	Q1 2026	Study ongoing			
	CKD in Type 1 Diabetes (<i>FINE-ONE</i>)			NCT05901831	Q1 2027	Study ongoing			
Vericiguat (sGC Stimulator)	Heart Failure (HFrEF) (<i>VICTOR²</i>)		Bayer				NCT05093933	Q1 2025	Study ongoing
Asundexian (FXIa Inhibitor) (<i>BAY 2433334</i>)	2° Stroke Prevention (<i>OCEANIC-STROKE</i>)		Bayer				NCT05686070	Q4 2025	Study ongoing
Congestive Heart Failure rAAV Gene Therapy (<i>AB-1002</i>)	Congestive Heart Failure (<i>GenePHIT</i>)		AskBio				NCT05598333	Q4 2029	Study ongoing
Anti-α2AP (<i>BAY 3018250</i>)	Acute Ischemic Stroke; Pulmonary Embolism (<i>SIRIUS</i>)		Bayer				NCT06149520	Q2 2025	Study ongoing
sGC Activator (<i>BAY 3283142</i>)	Chronic Kidney Disease (CKD)		Bayer				NCT05491642	Q1 2023	Study completed
SEMA 3a (<i>BAY 3401016</i>)	Alport Syndrome		Bayer/Evotec				n/a	Q3 2024	Study ongoing
Anti-coagulant (<i>BAY 3389934</i>)	Anti-coagulation		Bayer				n/a	Q2 2024	Study ongoing

Protein Therapeutics
 Cell Therapy
 Contrast Agent
 Genetic Medicine
 Radionuclide Therapy
 Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Conducted by Merck & Co ³ Including Precision Cardiovascular, Nephrology & Acute Care



Pharmaceuticals – Pipeline Details Neurol./Rare Dis.¹ (as of April 30, 2024)

Candidate Medication	Indication	Modality	Compound Origin	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Bemdaneprocel (Parkinson's Disease Cell Therapy) (<i>BRT-DA01</i>)	Parkinson's Disease		BlueRock				NCT04802733	Q2 2023	Study ongoing
Parkinson's Disease rAAV Gene Therapy (<i>AB-1005 aka AAV2-GDNF-PD</i>)	Parkinson's Disease		AskBio				NCT04167540	Q4 2023	Study ongoing
Multiple System Atrophy rAAV Gene Therapy (<i>AB-1005 aka AAV2-GDNF-MSA</i>)	Multiple System Atrophy		AskBio				NCT04680065	Q4 2025	Study ongoing
Pompe Disease rAAV Gene Therapy (<i>ACTUS-101</i>)	Pompe Disease		AskBio				NCT03533673	Q3 2022	Study ongoing
Huntington's Disease rAAV Gene Therapy (<i>AB-1001 aka BV-101</i>)	Huntington's Disease		AskBio				NCT05541627	Q4 2025	Study ongoing
LGMD2I/R9 rAAV Gene Therapy (<i>AB-1003 aka LION-101</i>)	Limb-Girdle Muscular Dystrophy 2i		AskBio				NCT05230459	Q4 2028	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



Pharmaceuticals – Pipeline Details Others¹ (as of April 30, 2024)

Candidate Medication	Indication	Modality	Compound Origin	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Elinzanetant (Neurokinin-1,3 Rec Antagonist)	Vasomotor Symptoms (OASIS-1, OASIS-2, OASIS-3, OASIS-4, NIRVANA ²)		KaNDy				NCT05042362 NCT05099159 NCT05030584 NCT05587296 NCT06112756	Q3 2023 Q2 2023 Q1 2023 Q1 2024 Q3 2024	Study completed Study completed Study completed Study ongoing Study ongoing
Aflibercept 8mg (VEGF Inhibitor)	Retinal Vein Occlusion (RVO) (QUASAR)		Regeneron				NCT05850520	Q4 2024	Study ongoing
Gadoquatrane (High Relaxivity Contrast Agent, HRCA)	Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OB)R)		Bayer				NCT05915702 NCT05915728	Q4 2024 Q4 2024	Studies ongoing
Runcaciguat (sGC Activator) (BAY 1101042)	Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)		Bayer				NCT04722991	Q2 2024	Study ongoing
GPR84 Antagonist (BAY 3178275)	Diabetic Neuropathic Pain		Bayer				n/a	Q1 2024	Study ongoing
BAY 2701250	Pulmonary Hypertension		Bayer				NCT06048120	Q1 2025	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Phase II pilot study on sleep disturbances associated with menopause